- Home
- PRSO vs MYNZ Comparison
PRSO vs MYNZ Comparison
Compare PRSO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSO
- MYNZ
- Stock Information
- Founded
- PRSO 2008
- MYNZ 2021
- Country
- PRSO United States
- MYNZ Germany
- Employees
- PRSO N/A
- MYNZ N/A
- Industry
- PRSO Semiconductors
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- PRSO Technology
- MYNZ Health Care
- Exchange
- PRSO Nasdaq
- MYNZ Nasdaq
- Market Cap
- PRSO 7.4M
- MYNZ 7.9M
- IPO Year
- PRSO 2001
- MYNZ 2021
- Fundamental
- Price
- PRSO $1.37
- MYNZ $1.60
- Analyst Decision
- PRSO Strong Buy
- MYNZ Buy
- Analyst Count
- PRSO 1
- MYNZ 2
- Target Price
- PRSO $3.00
- MYNZ $14.00
- AVG Volume (30 Days)
- PRSO 621.0K
- MYNZ 387.7K
- Earning Date
- PRSO 11-11-2025
- MYNZ 09-26-2025
- Dividend Yield
- PRSO N/A
- MYNZ N/A
- EPS Growth
- PRSO N/A
- MYNZ N/A
- EPS
- PRSO N/A
- MYNZ N/A
- Revenue
- PRSO $13,608,000.00
- MYNZ $659,935.00
- Revenue This Year
- PRSO N/A
- MYNZ $26.06
- Revenue Next Year
- PRSO $47.61
- MYNZ $4.97
- P/E Ratio
- PRSO N/A
- MYNZ N/A
- Revenue Growth
- PRSO 1.80
- MYNZ N/A
- 52 Week Low
- PRSO $0.52
- MYNZ $1.28
- 52 Week High
- PRSO $2.34
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- PRSO 61.34
- MYNZ 35.56
- Support Level
- PRSO $1.18
- MYNZ $1.55
- Resistance Level
- PRSO $1.35
- MYNZ $1.73
- Average True Range (ATR)
- PRSO 0.07
- MYNZ 0.12
- MACD
- PRSO 0.00
- MYNZ -0.01
- Stochastic Oscillator
- PRSO 88.87
- MYNZ 5.56
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.